About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNCT07316621

Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives

The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the dis...

Lead sponsor: GLSMED Learning Health S.A.•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Ana F Raimundo, PhD

CONTACT

+351 926139262 intercept@hospitaldaluz.pt

Sponsors

Lead Sponsor

GLSMED Learning Health S.A.

Age

16 - 35 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or female participants, between 16 and 35 years old
•FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
•Participants able to understand the information provided to them and to give written informed assent or consent for the study.

Exclusion Criteria

•Prior diagnosis of IBD
•Any legal or medical condition that limits the information and participation in the study
•Inability to verify CD diagnosis in the proband
•Participants unwilling or unable to provide informed written consent
•Participants unwilling or unable to donate blood for serum

Related studies

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394 · Inflammatory Bowel Disease (IBD), Crohn Disease (CD), and more

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420 · IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, and more

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

NCT06896305 · Ulcerative Colitis (UC), Crohn Disease (CD)

CEDUR - German IBD Registry

NCT07319442 · Ulcerative Colitis (UC), Indeterminate Colitis, and more

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07224113 · IBD, Crohn Disease (CD), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 5, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment10,000

Start dateJan 2026

Last updatedJan 5, 2026

Condition

Crohn Disease (CD)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions